抗西斯普拉丁的尿路膀癌细胞经历了超越华堡效应的代谢重编程
Julieta Afonso1,2, Catarina Barbosa-Matos1,2, Ricardo Silvestre1,2
1Life and Health Sciences Research Institute (ICVS), Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal.
Cancers
|April 13, 2024
概括
晚期泌尿器膀癌 (UBC) 中的西斯普拉丁耐药性涉及超越华堡效应的复杂代谢变化. 这些代谢变化是细胞特异性的,影响治疗反应和患者的结果.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 尿管膀癌 尿管膀癌
背景情况:
- 晚期泌尿道膀癌 (UBC) 的预后不佳.
- 化疗耐药性显著导致高死亡率.
- 在UBC中基底的思普拉丁耐药性机制尚未完全理解.
研究的目的:
- 为了研究先进的UBC细胞系对西斯普拉丁耐药性的代谢特征.
- 阐明与UBC中化学抵抗相关的代谢适应.
主要方法:
- 利用了三对同位素的UBC细胞系 (亲细胞系和抗西斯普拉丁细胞系).
- 使用功能测定和实时代谢学进行了代谢查.
- 评估糖解,呼吸和其他代谢途径.
主要成果:
- 抗西斯普拉丁的UBC细胞表现出恶化的糖分代谢 (华堡表型),特别是HT1376R细胞.
- HT1376R细胞显示呼吸减少和细胞外酸性增加.
- KU1919R细胞显示了新陈代谢对氧化酸化的重新连接.
- 耐药细胞表现出涉及乳酸,脂质和谷氨酸代谢的代谢转变.
结论:
- 抗西斯普拉丁的UBC细胞经历了超越Warburg效应的显著代谢变化.
- 代谢适应是细胞系依赖的,这表明有不同的抵抗机制.
- 了解这些代谢变化对于改善UBC治疗策略至关重要.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


